SAN DIEGO, CA--(Marketwire - March 04, 2008) - Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Cypress has closed the previously announced acquisition of Proprius Pharmaceuticals, Inc. The transaction included an upfront payment of approximately $37.5 million in cash as well as an additional $37.5 million in potential milestone-related payments associated with the development of Proprius’ therapeutic candidates.
